A monthly figure will not compare cleanly across these three, because they sell different bundles. Noom charges one subscription that can cover clinical evaluations, laboratory testing and in some cases the medication itself. Hims and Ro are medication-first telehealth platforms where the drug is the dominant line item. Coverage differs again, and it is not a property of the platform.
What each subscription is actually buying
Noom started as a behavior-change product and later added clinical services, and its published terms describe the result plainly. Pricing for its medication program is combined into a single subscription that may include charges for medical evaluations, laboratory tests and, for some product selections, prescription medication dispensed by pharmacy partners, with Noom acting as collection agent and passing those amounts to the clinical partners. One charge, several vendors behind it.
Hims and Ro were built the other way around. Both run multi-category telehealth, with weight management sitting alongside other treatment areas, and in both cases the recurring charge is anchored to a prescription rather than to a curriculum. Coaching, where it exists, is a support layer around the medication rather than the product being sold.
That structural difference decides what a low headline number means. A bundle priced below a medication-first plan may simply exclude the drug from the bundle for that particular selection. A medication-first plan priced below a bundle is not including a habit program at all. Neither is a discount on the other.
Coverage is a property of the plan, not the provider
None of these three is an insurer, and the coverage question separates into three different routes. Noom’s terms state that the company is not enrolled as a participating provider or vendor with federal or state healthcare programs including Medicare and Medicaid, that services accessed directly are available on a cash-pay basis, and that neither side will submit claims to those payors. A separate section covers employer and health plan customers, where clinical partners may file claims and copays and deductibles can apply.
Ro’s weight program advertises an insurance benefit check as a step in onboarding, with a stated turnaround of a few weeks, and describes routing to cash-pay options for approved GLP-1 products when coverage does not come through. That is a genuinely different shape of process from a flat cash subscription, and it changes the timeline before a first dose as much as it changes the price.
Underneath all of it sits plan design. Medicare drug benefits have excluded agents prescribed only for weight reduction, which is a statutory question rather than a provider policy, and commercial coverage of anti-obesity medication varies by employer and by state benchmark plan. A reader whose plan covers the category will usually find the copay route cheaper than every cash program discussed here, and a reader whose plan excludes it is comparing cash prices no matter which brand name is on the app.
Since none of these platforms is an insurer, the work of decoding a benefit falls on whatever guidance each one publishes, and providers handle that unevenly. Ro runs a benefit check inside onboarding, LillyDirect steers patients toward manufacturer savings on brand products, and providers such as HealthRX post a plain-language explainer on GLP-1 insurance coverage that a shopper can read before creating an account, while Hims and Hers leans on cash-pay simplicity instead. Reading each provider’s own coverage material before intake is what tells a buyer which route their particular plan will actually reward.
The line items that move after month one
Entry pricing is the least stable part of any of these offers, and three items reliably shift it. The first is dose escalation. Titration schedules step upward over months, real-world data shows a meaningful share of patients never reaching the higher maintenance doses, and programs differ on whether a higher dose costs more. The second is laboratory work, which may be bundled, billed separately, or waived. The third is the pathway itself.
Brand products such as Wegovy and Zepbound carry approved labeling and manufacturer list prices. Compounded semaglutide and compounded tirzepatide are pharmacy preparations that are not FDA-approved, meaning the agency has not reviewed them for safety, effectiveness or manufacturing quality. Cash-pay compounded programs are usually the cheapest column on any spreadsheet, and the reason is regulatory rather than promotional. Among providers publishing a flat monthly figure that states the pathway alongside the price, Henry Meds, Mochi and FormBlends put both facts in the same place, while several larger platforms display a starting rate and settle the rest after intake. Both approaches exist legitimately, but only the first allows arithmetic before payment.
| Cost factor | Bundled behavior program with clinical services | Medication-first telehealth platform | What to confirm in writing |
|---|---|---|---|
| What the recurring charge covers | Coaching, clinician access, sometimes labs and medication in one price | Clinical access plus the prescription, coaching as a support layer | Whether the drug is inside or outside the quoted figure |
| Insurance interaction | Direct route commonly cash-pay only; employer route may bill claims | Benefit check may run before a cash fallback | Whether claims are filed at all, and by whom |
| Dose escalation | May be inside the subscription or trigger a new price tier | Frequently tied to the dose supplied that month | The price at the maintenance dose, not the starting dose |
| Laboratory testing | Sometimes collected within the subscription price | Often ordered separately or not required | Who bills for labs and at what rate |
| Medication pathway | Brand or compounded, and some compounded items ship only from specific pharmacies | Brand, compounded, or both depending on the program | Which pathway, named before checkout |
| Exit terms | Refund rules vary by state of residence | Notice period and prepaid balance handling | The exact action that stops billing |
Cancellation terms are part of the price
The cost of leaving belongs in the comparison, because it is the part buyers discover last. Noom’s published refund policy treats fees as non-refundable outside promotions, with a separate cancellation and refund route set out for California residents. Subscription telehealth generally works the same way: the charge recurs until a specific action is taken, and prepaid multi-month blocks convert an apparent discount into a commitment.
Read that section before the pricing page. A higher monthly rate with a clean month-to-month exit can cost less over a year than a discounted quarterly plan abandoned in week six.
Frequently asked questions
Why is one price higher when the medication looks the same?
Because the bundle differs and the pathway differs. A subscription covering clinician time, labs and coaching is buying more services than one covering a prescription alone, and an approved brand product carries a very different acquisition cost from a compounded preparation. The molecule name on the label does not settle either question.
Does an insurance benefit check make a program cheaper?
Only if the plan covers the category. A check adds a step and some waiting time, and it produces savings when a plan includes anti-obesity medication with prior authorization satisfied. Where the plan excludes the category outright, the result is the same cash price arrived at a few weeks later.
Should the starting dose price be used for budgeting?
No. Titration moves upward over several months, and the maintenance dose is where a patient spends most of the year. Asking for the price at the highest dose the program supplies, and whether escalation requires a new charge, produces a far more realistic annual figure than the introductory rate.
Are employer-sponsored versions comparable to the direct ones?
Not closely. An employer or health plan route can involve claims filed by clinical partners, copays and deductibles under the plan documents, and eligibility rules the individual did not choose. Someone buying directly is in a cash market with different economics, so pricing anecdotes from benefit users transfer poorly.
What single question exposes the most hidden cost?
Asking what the total charge will be in month six at the maintenance dose, including labs, shipping and any supplies. That one question forces every excluded item into view at once, and a program unwilling to answer it in writing has revealed something useful about how its pricing is constructed.
By
